Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3, providing an innovative framework for pancreatic cancer treatment, especially in combination with EGFR inhibitors [60]. Here, EGFR is linked to familial pancreatic carcinoma.